ALPHAMAB ONCOLO.DL-000002 (3NK) — Cash Flow Quality Index
ALPHAMAB ONCOLO.DL-000002 (3NK) has a Cash Flow Quality Index of 1.28x as of December 2024. Operating cash flow of €212.34 Million exceeds net income of €166.34 Million, indicating high earnings quality where cash backs reported profits. Also explore balance sheet size of ALPHAMAB ONCOLO.DL-000002 for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
ALPHAMAB ONCOLO.DL-000002 Cash Flow Quality Index (2024–2024)
Historical Cash Flow Quality Index for ALPHAMAB ONCOLO.DL-000002 across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check tangible equity quality of ALPHAMAB ONCOLO.DL-000002 to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for ALPHAMAB ONCOLO.DL-000002 (2024–2024)
Year-by-year earnings quality comparison for ALPHAMAB ONCOLO.DL-000002. For live market cap and the full company financial profile, see ALPHAMAB ONCOLO.DL-000002 stock valuation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.28x | €212.34 Million | €166.34 Million | — |